All In Biotech

Drug Trial Radar · NCT07509684

A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

An Open-label, Multicenter Phase Ib/II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Injectable ALK-N001 in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Dec 2027

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, dose-escalation and cohort-expansion Phase Ib/II clinical trial conducted in patients with advanced solid tumors, aiming to evaluate the safety, pharmacokinetics and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • ALK-N001 for InjectionDrug

    The drug is administered via intravenous infusion at a constant rate over 2 hours ± 20 minutes. The primary dosing schedule was every 2 weeks (Q2W) in a 28-day cycle, while an every 3 weeks (Q3W) schedule with a 21-day cycle was also explored.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Through study completion, an average of 2 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.